$ARWR
ARROWHEAD PHARMACEUTICALS, INC.

2017 Q1 Form 10-Q Financial Statement

#000156459017001023 Filed on February 06, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q3
Revenue $8.986M $4.365M $31.25K
YoY Change 20439.27% 9878.28% -28.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.950M $8.550M $13.12M
YoY Change -33.68% 3.64% 8.07%
% of Gross Profit
Research & Development $11.44M $9.527M $11.67M
YoY Change 14.15% -7.85% 12.32%
% of Gross Profit
Depreciation & Amortization $1.200M $1.200M $900.0K
YoY Change 50.0% 50.0% 12.5%
% of Gross Profit
Operating Expenses $15.12M $19.27M $19.78M
YoY Change -29.06% -0.61% -21.73%
Operating Profit -$6.130M -$14.90M -$21.80M
YoY Change -71.17% -22.95% -13.62%
Interest Expense $108.7K $25.15K -$480.0K
YoY Change 37.55% -74.95% -187.27%
% of Operating Profit
Other Income/Expense, Net $10.00K $2.816M $60.00K
YoY Change -97.77% 3563.71% -185.71%
Pretax Income -$6.040M -$12.09M -$22.22M
YoY Change -70.98% -37.26% -10.19%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.043M -$12.09M -$22.22M
YoY Change -70.97% -37.26% -10.2%
Net Earnings / Revenue -67.24% -276.86% -71110.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$80.93K -$169.2K -$342.3K
COMMON SHARES
Basic Shares Outstanding 74.57M 74.17M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.60M $102.1M $85.40M
YoY Change 40.81% 33.29% -13.56%
Cash & Equivalents $61.72M $102.1M $85.37M
Short-Term Investments $24.90M $0.00
Other Short-Term Assets $2.400M $3.495M $3.771M
YoY Change -48.94% -38.68% 357.88%
Inventory
Prepaid Expenses $569.4K $1.290M
Receivables $600.0K $100.0K $75.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $89.70M $106.2M $90.50M
YoY Change 35.7% 29.04% -12.03%
LONG-TERM ASSETS
Property, Plant & Equipment $15.70M $16.20M $15.40M
YoY Change 256.82% 244.68% 240.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $122.3K $122.3K
YoY Change 100.0% 167.17%
Total Long-Term Assets $37.20M $38.06M $37.70M
YoY Change 30.53% 30.78% 28.25%
TOTAL ASSETS
Total Short-Term Assets $89.70M $106.2M $90.50M
Total Long-Term Assets $37.20M $38.06M $37.70M
Total Assets $126.9M $144.3M $128.2M
YoY Change 34.14% 29.5% -3.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $3.698M $12.20M
YoY Change -65.33% -30.22% 142.46%
Accrued Expenses $3.000M $4.762M $8.600M
YoY Change -42.31% -10.15% 59.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $27.60M $37.00M $25.64M
YoY Change 95.74% 200.13% 61.28%
LONG-TERM LIABILITIES
Long-Term Debt $2.400M $2.500M $2.500M
YoY Change 500.0% 400.0% 400.0%
Other Long-Term Liabilities $3.600M $7.600M $200.0K
YoY Change -41.94% 2159.03% 0.0%
Total Long-Term Liabilities $6.000M $10.10M $7.508M
YoY Change -9.09% 51.09% 11.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.60M $37.00M $25.64M
Total Long-Term Liabilities $6.000M $10.10M $7.508M
Total Liabilities $33.00M $46.50M $33.15M
YoY Change 64.18% 144.57% 46.39%
SHAREHOLDERS EQUITY
Retained Earnings -$398.4M
YoY Change 25.8%
Common Stock $162.1K
YoY Change 6.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.90M $97.80M $95.58M
YoY Change
Total Liabilities & Shareholders Equity $126.9M $144.3M $128.2M
YoY Change 34.14% 29.56% -3.09%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$6.043M -$12.09M -$22.22M
YoY Change -70.97% -37.26% -10.2%
Depreciation, Depletion And Amortization $1.200M $1.200M $900.0K
YoY Change 50.0% 50.0% 12.5%
Cash From Operating Activities -$14.30M $10.00M -$10.20M
YoY Change -3.38% -147.39% -15.0%
INVESTING ACTIVITIES
Capital Expenditures -$1.400M $5.297M -$2.800M
YoY Change 1300.0% 1202.63% 211.11%
Acquisitions
YoY Change
Other Investing Activities -$24.80M $0.00 $1.000M
YoY Change -875.0% -100.0% -85.07%
Cash From Investing Activities -$26.20M -$5.300M -$1.800M
YoY Change -945.16% -303.85% -131.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $12.50M $43.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 12.00M 53.60M
YoY Change -200.0% -2500.0% 53500.0%
NET CHANGE
Cash From Operating Activities -14.30M 10.00M -10.20M
Cash From Investing Activities -26.20M -5.300M -1.800M
Cash From Financing Activities 200.0K 12.00M 53.60M
Net Change In Cash -40.30M 16.70M 41.60M
YoY Change 238.66% -187.89% -781.97%
FREE CASH FLOW
Cash From Operating Activities -$14.30M $10.00M -$10.20M
Capital Expenditures -$1.400M $5.297M -$2.800M
Free Cash Flow -$12.90M $4.703M -$7.400M
YoY Change -12.24% -121.87% -33.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Document Type
DocumentType
10-Q
CY2016Q4 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2016Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q4 dei Trading Symbol
TradingSymbol
ARWR
CY2016Q4 dei Entity Registrant Name
EntityRegistrantName
ARROWHEAD PHARMACEUTICALS, INC.
CY2016Q4 dei Entity Central Index Key
EntityCentralIndexKey
0000879407
CY2016Q4 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1483831
CY2016Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74569706
CY2016Q4 dei Amendment Flag
AmendmentFlag
false
CY2016Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2424442
CY2015Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2380343
CY2016Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1185611
CY2015Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
794349
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1306800
CY2016Q4 us-gaap Profit Loss
ProfitLoss
-12086108
CY2015Q4 us-gaap Profit Loss
ProfitLoss
-19264414
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59548672
CY2016Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-381564
CY2016Q4 us-gaap Share Based Compensation
ShareBasedCompensation
2424442
CY2015Q4 us-gaap Share Based Compensation
ShareBasedCompensation
2380343
CY2015Q4 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
108403
CY2016Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15000
CY2015Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1054719
CY2016Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1027021
CY2015Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
490057
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7508452
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3495369
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2150014
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
197713
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2500000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
569415
CY2016Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
2533455
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5180115
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
440580
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21739761
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
75000
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1289923
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85366448
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3771172
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122333
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
440580
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22164868
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145000000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69746685
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2188703
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
19385020
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122333
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1951609
CY2016Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12278716
CY2016Q4 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-192608
CY2015Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45818
CY2015Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19218596
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69746685
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
19267383
CY2016Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2424442
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2815779
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12086108
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2274997
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2482775
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398435043
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15652
CY2016Q3 us-gaap Minority Interest
MinorityInterest
-555188
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128176505
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15652
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
95579447
CY2016Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
95024259
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9527051
CY2015Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10338833
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14901887
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19341270
CY2016Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25148
CY2016Q4 us-gaap Assets
Assets
144258106
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3698297
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4762105
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7449
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19264414
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76856
CY2016Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
442915
CY2016Q4 arwr Research Equipment
ResearchEquipment
8729818
CY2016Q3 arwr Research Equipment
ResearchEquipment
7490400
CY2016Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
107871
CY2016Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
80841
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
12000074
CY2016Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
11885365
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21438922
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19899521
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5273263
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4512760
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1854174
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71444600
CY2016Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16739121
CY2015Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19049266
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81214354
CY2016Q4 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
25652536
CY2016Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4648013
CY2015Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
257216
CY2016Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1850996
CY2015Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3945503
CY2016Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-235471
CY2015Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
42789
CY2016Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10000191
CY2015Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21148069
CY2016Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5296653
CY2015Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
406612
CY2015Q4 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3000000
CY2016Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5296653
CY2015Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2593388
CY2016Q4 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
47277
CY2015Q4 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
54051
CY2016Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
417140
CY2015Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
440534
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12500000
CY2016Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12035583
CY2015Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-494585
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62165088
CY2016Q4 us-gaap Interest Paid
InterestPaid
48195
CY2015Q4 us-gaap Interest Paid
InterestPaid
3054
CY2016Q4 arwr Property And Equipment Expenditures Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentExpendituresIncludedInAccountsPayableAndAccruedExpenses
1041276
CY2016Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p></div>
CY2015Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
438991
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1275322
CY2016Q4 arwr Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.30
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2016Q4 us-gaap Investments
Investments
0
CY2016Q3 us-gaap Investments
Investments
0
CY2016Q4 arwr Fair Value Of Contingent Consideration Obligation
FairValueOfContingentConsiderationObligation
0
CY2016Q3 arwr Fair Value Of Contingent Consideration Obligation
FairValueOfContingentConsiderationObligation
0
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
601159
CY2016Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
425107
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1700429
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1700429
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1700429
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1700429
CY2016Q4 arwr Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
1700429
CY2016Q4 arwr Finite Lived Intangible Assets Amortization Expense After Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearSix
11962294
CY2016Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
150000000
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
527181
CY2016Q4 arwr Facility Rent Expense
FacilityRentExpense
381100
CY2015Q4 arwr Facility Rent Expense
FacilityRentExpense
198600
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1118650
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1531765
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1435409
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1044431
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1070496
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5766495
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11967246
CY2016Q4 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
146963
CY2016Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
208506
CY2016Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
223820
CY2016Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
240258
CY2016Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
257903
CY2016Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
1603038
CY2016Q4 us-gaap Contractual Obligation
ContractualObligation
2680488
CY2016Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2016Q4 us-gaap Purchase Obligation
PurchaseObligation
12400000
CY2016Q4 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
12400000
CY2016Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6691200
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
48000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
513856
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6225344
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4152293
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.56
CY2016Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.50
CY2016Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.24
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.50
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.26
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0134
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0141
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0181
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.79
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.49
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.46
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
At vesting, each existing RSU will be exchanged for one share of the Company’s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes withheld upon vesting and withholds a number of shares of equal value.
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1454831
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-21574

Files In Submission

Name View Source Status
0001564590-17-001023-index-headers.html Edgar Link pending
0001564590-17-001023-index.html Edgar Link pending
0001564590-17-001023.txt Edgar Link pending
0001564590-17-001023-xbrl.zip Edgar Link pending
arwr-10q_20161231.htm Edgar Link pending
arwr-20161231.xml Edgar Link completed
arwr-20161231.xsd Edgar Link pending
arwr-20161231_cal.xml Edgar Link unprocessable
arwr-20161231_def.xml Edgar Link unprocessable
arwr-20161231_lab.xml Edgar Link unprocessable
arwr-20161231_pre.xml Edgar Link unprocessable
arwr-ex311_8.htm Edgar Link pending
arwr-ex312_9.htm Edgar Link pending
arwr-ex321_10.htm Edgar Link pending
arwr-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending